Weekly Digest – October 2026 Weekly Digest – October 2026 25 September 2026: Perioperative Imfinzi plus Enfortumab vedotin received U.S. FDA Priority Review for MIBC AstraZeneca announced that the U.S. FDA has accepted supplemental Biologics License Application for Imfinzi in […]
Weekly Digest – October 2026 Weekly Digest – October 2026 28 September 2026: BL-M05D1 received BTD in China for previously treated advanced Gastric/GEJ cancer Biokin Pharma announced that BL-M05D1, its Claudin18.2-directed ADC, has been included in China’s NMPA Breakthrough Therapy […]
Weekly Digest – October 2026 Weekly Digest – October 2026 25 September 2026: Ifinatamab deruxtecan BLA for previously treated extensive-stage SCLC was voluntarily withdrawn in the U.S. Daiichi Sankyo and MSD announced the voluntary withdrawal of the U.S. BLA seeking […]
Weekly Digest – October 2026 Weekly Digest – October 2026 28 September 2026: AstraZeneca announced an equity investment and clinical collaboration with Summit Therapeutics to advance ADC combinations in cancer AstraZeneca announced a US$2 billion strategic equity investment in Summit […]
Weekly Digest – October 2026 Weekly Digest – October 2026 29 September 2026: Nurix Therapeutics announced a $7 million milestone achievement under its strategic collaboration with Pfizer Nurix Therapeutics announced the achievement of a US$7 million research milestone under its […]
Weekly Digest – October 2026 Weekly Digest – October 2026 01 October 2026: Dong-A ST and Galux entered a research collaboration to develop AI-designed antibodies for ADC therapeutics Dong-A ST and Galux announced a research collaboration to develop novel ADC […]
